Clinical Trial

Advanta VXT and Flixene PMCF Registry

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of the registry is to evaluate the long-term safety and performance of Advanta VXT and Flixene vascular grafts for repair or replacement of peripheral arteries. This registry is also intended to provide further data on the clinical usefulness of the Advanta VXT and Flixene vascular grafts.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-04; most recent amendment 2026-03-11.
Status change: Not Yet Recruiting → Recruiting 2025-11-11
Trial Details
NCT Number NCT07161583
Lead Sponsor Atrium Medical Corporation
Conditions Peripheral Arterial Disease
Enrollment 1,000 participants
Start Date 2025-09-25
Primary Completion 2026-09 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-13